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Abstract. Triple-negative breast cancer (TNBC) is a very 
aggressive type of tumour and its aggressiveness is linked to 
E-cadherin downregulation. In estrogen-sensitive breast cancer, 
high levels of E-cadherin fit with high levels of ERα and MTA3 
(a component of the transcription Mi-2/NuRD complex with 
intrinsic DAC activity). In TNBC the E-cadherin downregula-
tion could be due to epigenetic silencing of the CDH1 gene 
as well as to the lack of a fully functioning ERα-activated 
pathway. We report that the pan-histone deacetylase inhibitor 
LBH589, a potent anti-proliferative agent, induced E-cadherin 
expression on cell membranes of MDA-MB-231 cells (TNBC), 
determining a reduction of cell invasion and migration. Even 
though E-cadherin expression in breast cancer is also regulated 
by estradiol and the ERα/MTA3/Snail/Slug pathway, LBH589 
is able to increase E-cadherin without affecting the estrogen 
pathway. In fact, no expression of ERα, PR and FoxA1 was 
observed in MDA-MB-231 cells before and after LBH589 treat-
ment; furthermore, the drug caused an increase in Snail and 
Slug expression with a concomitant reduction of MTA3 levels. 
Taking into consideration its anti-proliferative and anti-invasive 
properties, we suggest the use of LBH589 in aggressive breast 
cancer refractory to hormonal therapy.
Introduction
Breast cancer, the most common cancer in women all over the 
world (1), is generally managed with success thank to avail-
able treatments (2). Regrettably, resistance to conventional 
therapy and increasing in metastatic and aggressive disease 
are emerging problems (3,4). A particular aggressive subtype 
of breast cancer is the triple-negative breast cancer (TNBC) 
that is defined by the absence of ER, PR and Her2/neu (5,6). 
TNBC generally occurs more frequently in younger women, 
frequently presents early metastatic spread and has poor 
overall prognosis (7,8).
In breast cancer, as well as in other tumour types, 
epigenetic modifications are considered a crucial mechanism 
involved in cancer growth, dedifferentiation and aggressive-
ness; indeed, epigenetic deregulation can alter a number of 
molecular pathways involved in the control of cell function. 
Epigenetic drugs, able to restore normal epigenome in cancer 
cells, are under extensive pharmacological research (9). In 
breast cancer, histone acetylation state is considered of great 
importance. Histone acetylation and deacetylation, controlled 
by the enzymes histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), affect chromatin conformation and, 
therefore, gene transcription, DNA repair and replication, 
and cell cycle checkpoints (10). Altered expression of HDACs 
has been reported in breast cancer by several authors (11,12). 
Therefore, HDAC inhibitors (DCI) are considered valuable 
therapeutic tools and have been under extensive evaluation. 
DCI vorinostat (13), for example, in association with paclitaxel 
and bevacizumab induced a partial or complete response in 
>50% of patients with metastatic breast cancer. The anti-
proliferative and re-differentiating effect of several DCI was 
reported in vitro by a number of laboratories (14-17). In recent 
years, the pan-deacetylase inhibitor panobinostat (LBH589) 
has been taken into consideration. Our laboratory demonstrated 
for the first time that LBH589 in nanomolar concentration is 
a potent antiproliferative agent in ER-positive and -negative 
breast cancer cells, and that its anticancer activity is sustained 
by H4 histone acetylation (18).
It is so well known that ERα is the hallmark of breast 
cancer estrogen sensitivity and good response to tamoxifen 
therapy (19) and that it can be lost during disease progression, 
giving rise to hormone-independent and aggressive pheno-
type (20). Epigenetic deregulation has also been considered 
one of the possible causes of ERα loss in breast cancer (e.g., 
histone tail deacetylation and methylation or methylation of 
the CpG islands in the ER promoter) (21). Hence, DCI were 
exhaustively studied also for their ability to restore ERα 
and its pathway in ER-negative breast cancer cells. VPA, for 
The pan-histone deacetylase inhibitor LBH589 (panobinostat) 
alters the invasive breast cancer cell phenotype
NICOLETTA FORTUNATI1,  FRANCESCA MARANO2,  ANDREA BANDINO3,  ROBERTO FRAIRIA2,   
MARIA GRAZIELLA CATALANO2  and  GIUSEPPE BOCCUZZI2
1Oncological Endocrinology, AO Città della Salute e della Scienza di Torino; 2Department of Medical Sciences, 
University of Turin, I-10126 Torino; 3Department of Oncology, Biochemistry Section, 
University of Turin, I-10100 Torino, Italy
Received September 10, 2013;  Accepted October 22, 2013
DOI: 10.3892/ijo.2013.2218
Correspondence to: Dr Nicoletta Fortunati, Oncological Endo-
crinology, AO Città della Salute e della Scienza di Torino, Via 
Genova 3, I-10126 Torino, Italy
E-mail: nfortunati@cittadellasalute.to.it
Key words: E-cadherin, estrogen receptor, DCI, triple-negative 
breast cancer, epigenetic
FORTUNATI et al:  E-CADHERIN CONTROL BY LBH589 IN TNBC2
example, was demonstrated by us (16) and by other authors 
(14) to restore estrogen and, thus, antiestrogen sensitivity in 
MDA-MB-231 cells considered a good model of TNBC; 
LBH589 was shown either to induce ERα in MDA-MB-231 
cells (22), or not to have any detectable effect (23,24).
Estradiol sensitivity is also strictly linked to aggressive-
ness of breast cancer cells. Aggressive breast tumours are 
characterized by E-cadherin downregulation that switches on 
the phenomenon called epithelial-to-mesenchimal transition 
(EMT), the corner stone of tumour spreading and metastasis 
(25). E-cadherin downregulation is mainly due to epigenetic 
alterations of CDH1 gene promoter (26,27) or by epigenetic 
controlled overexpression of several E-cadherin transcrip-
tional repressors, such as Snail/SNAI1, Slug/SNAI2, SIP1/
ZEB2 or Twist (28-32).
In breast cancer, estradiol (E2)/ERα and MTA3/Snail/
E-cadherin signalling pathways are intimately linked (33). 
Estradiol-activated ERα induces MTA3, a member of the 
histone deacetylase Mi-2/NuRD macro-complex, that down-
regulates Snail, upregulating E-cadherin (34). The absence of 
estrogen receptor or MTA3 leads to aberrant expression of the 
transcriptional repressor Snail and consequent inhibition of 
E-cadherin (30).
E-cadherin and its regulators are considered attractive 
therapeutic targets, in order to inactivate cell invasion and 
metastasis.
The aim of the present study was to evaluate the effect 
of the pan-deacetylase inhibitor panobinostat (LBH589) on 
expression and function of ERα and its cognate proteins PR 
(progesterone receptor) and FoxA1 (forkhead box A1), and 
of E-cadherin and its repressors Snail and Slug, in TNBC 
MDA-MB-231 cells.
Materials and methods
Cell lines and reagents. Triple-negative breast cancer cell line 
MDA-MB-231 and estrogen receptor-positive MCF-7 cells 
were purchased from ECACC (Salisbury, UK), which certifies 
the origin and identity of the cells. Moreover, none of the cell 
lines are included in the database of cross-contaminated or 
misidentified cell lines (http://www.hpacultures.org.uk/ 
services/celllineidentityverification/misidentifiedcelllines.jsp). 
Cells were routinely maintained at 37˚C, in 5% CO2 and 
95% humidity, in RPMI-1640 (Sigma, St. Louis, MO, USA) 
with 100 IU/ml penicillin and 100 µg/ml streptomycin added, 
supplemented with 10% heat-inactivated FCS (Euroclone, 
Wetherby, UK). LBH589 was provided by Novartis Pharma 
AG (Basel, Switzerland), prepared as a 5 mM stock solution in 
DMSO and stored at -20˚C.
Gene expression: evaluation with real-time PCR. Cells (1x106) 
were seeded in 75-cm2 flasks and treated with LBH589 
(5-50 nM). Total RNA was extracted using TRIzol reagent 
(Invitrogen Ltd., Paisley, UK), as previously described. DNase I 
was added to remove remaining genomic DNA. Total RNA 
(1 µg) was reverse-transcribed with iScript cDNA Synthesis 
Table I. Primers for real-time PCR.
CDH1 Sense: 5'-TTGAAAGAGAAACAGGATGGCTG-3'
 Antisense: 5'-TCATTCTGATCGGTTACCGTGAT-3'
ERα  Sense: 5'-TGT GTC CAG CCA CCA ACC AG-3'
 Antisense: 5'-TTC AAC ATT CTC CCT CCT CTT CGG-3'
PR Sense: 5'-GCA TCA GGC TGT CAT TAT GGT GTC-3'
 Antisense: 5'-CAT AAG TAG TTG TGC TGC CCT TCC-3'
FoxA1 Sense: 5'-GGG TGG CTCCAG GAT GTT AGG-3'







β-ACT Sense: 5'-GCG AGA AGA TGA CCC AGA TC- 3'
 Antisense: 5'-GGA TAG CAC AGC CTG GAT AG-3'
β2-microglobulin Sense: 5'-AGA TGA GTA TGC CTG CCG TGT G-3'
 Antisense: 5'-TCA ACC CTC CAT GAT GCT GCT TAC-3'
L13Α Sense: 5'-GCA AGC GGA TGA ACA CCA ACC-3'
 Antisense: 5'-TTG AGG GCA GCA GGA ACC AC-3'
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kit (Bio-Rad Laboratories, Inc.), following the manufacturer's 
protocol.
Primers (Table I) were designed using Beacon Designer 5.0 
software according to parameters outlined in the Bio-Rad 
iCycler manual. Specificity of primers was confirmed by 
BLAST analysis. Real-time PCR was performed using a 
Bio-Rad iQ iCycler Detection system (Bio-Rad Laboratories, 
Inc.) with SYBR green fluorophore. Reactions were performed 
in a total volume of 25 µl, including 12.5 µl IQ SYBR Green 
Supermix (Bio-Rad Laboratories, Inc.), 1 µl of each primer 
at 10 µM concentration, and 5 µl of the previously reverse-
transcribed cDNA template. Protocol for primer set was 
optimized using seven serial 5X dilutions of template cDNA 
obtained from cells in basal conditions.
The protocol used is as follows: denaturation (95˚C for 
5 min), amplification repeated 40 times (95˚C for 15 sec, 60˚C 
for 1 min). A melting curve analysis was performed following 
every run to ensure a single amplified product for every reac-
tion. All reactions were carried out at least three times for each 
sample. Every gene expression level was normalized on the 
expression level of three house-keeping genes (β-actin, L13A, 
β-2-microglobulin).
Immunoblotting. Sub-confluent breast cancer cells were treated 
with LBH589 (25 nM) for 24 h and then they were harvested 
and lysed in the presence of lysis buffer (0.5% Triton X-100, 
2.5 mM EGTA, 5 mM MgCl2, 50 mM NaH2PO4) for 2 min 
on ice. Soluble cytosolic fraction was recovered and stored at 
-80˚C. The insoluble membrane fraction was dissolved in SDS 
sample buffer (TrizmaBase 0.2 M, glycerol 50%, SDS 10%), 
recovered and stored at -80˚C.
SDS-PAGE was performed on gels, loading 30 µg protein/
well. Separated proteins were electro-transferred onto PVDF 
membrane and probed with anti-E-cadherin antibody (1:1,000 
dilution, Sigma). PVDF membrane was then stripped and 
re-probed with an anti-α-tubulin antibody (clone 6-11B-1, 
1:2,000 dilution, Sigma) to check protein loading. Proteins 
were detected with Pierce Super Signal chemiluminescent 
substrate following the manufacturer's instructions. Bands 
were photographed and analyzed using Kodak 1D Image 
analysis software.
Immunofluorescence microscopy. Cells (4x103) were seeded in 
96-well plates and treated with 25 nM LBH589 for 24 h. After 
treatment, cells were fixed in PFA 1% and incubated with 
polyclonal anti-E-cadherin antibody (1:100 dilution, Sigma) at 
4˚C overnight. Then cells were washed with PBS containing 
0.5% Triton and 0.05% NaN3 followed by detection with anti-
rabbit Cy3-conjugated secondary antibody (1:1,000 dilution, 
GE Healthcare Europe, GmbH, Milan, Italy) in PBS plus 
0.5% Triton and 0.05% NaN3 for 2 h. Nuclear staining was 
obtained by treating cells with Hoechst 33258 (500 ng/ml in 
DMSO) in PBS. Cells were washed twice with distilled water 
and mounted with 50% glycerol-PBS media.
Scratch wound assay. Cells (2x105) were seeded in 6-well 
plates. Cells were treated with 25 nM LBH589 for 24 h and 
afterwards cell monolayer was gently wounded by scratching. 
The cells were washed twice with cooled PBS and incubated 
for further 24 h either in the absence or presence of 25 nM 
LBH589. For each wound, pictures were taken in the same field 
and the distance between the wound edges was analyzed using 
the ImageJ 1.42 software. For each condition, the percentage 
of the wound recovery in respect to the wound area at 0 h, was 
calculated.
Invasion assay. Cells (5x105) were seeded in 75-cm2 flasks and 
treated with LBH589 (25 nM). After 24 h, 2x105 cells were 
seeded in the BD BioCoat™ BD Matrigel™ invasion chamber 
(BD Biosciences Discovery Labware, Two Oak Park, Bedford, 
Figure 1. Effect of LBH589 on ERα, PR and FoxA1 gene expression in MCF-7 
cells. ERα, PR and FoxA1 mRNA was evaluated in MCF-7 cells treated 
with increasing doses of LBH589 with real-time PCR. Results were normal-
ized for three different housekeeping genes (β-actin, β2-microglobulin and 
L13A) and expressed as relative expression fold vs untreated controls (0). 
Results are expressed as the means ± SD; n=3; ***P<0.001. The evaluation 
was performed also in MDA-MB-231 cells; no expression of ERα, PR and 
FoxA1 mRNA was detectable either in basal condition or after LBH589 
treatment.
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MA, USA) and stimulated with 25 nM LBH589 for 24 h. At 
completion, the lower surfaces of the membrane were fixed 
with methanol and stained with crystal violet solution, to point 
out cells that migrated across the Matrigel and invaded the 
inferior face of the membranes. The number of cells that had 
migrated to the basal side of the membrane was quantified by 
counting 12 independent fields under the microscope.
Luciferase assay. Cells (2.5x105) were seeded in 6-well plates. 
After 24 h, cells were transfected with 1 µg of pGL2Basic-
EcadK1 plasmid/well using Lipofectin reagent (Invitrogen 
Ltd.). The plasmid (Promega Italia, Milan, Italy) contains 
the human CDH1 promoter sequences from -108 to +125 
linked to the luciferase gene as reporter (17). After transient 
transfection, cells were treated with 25 nM LBH589 for 24 h. 
Luciferase activity was assayed with the Luciferase assay 
system (Promega Corp., Madison, WI, USA).
Statistical analysis. Data are expressed throughout as the 
means ± SD, calculated from at least three different experi-
ments. Comparison between groups was performed with 
analysis of variance (one-way ANOVA) and the threshold of 
significance was calculated with the Bonferroni test. Statistical 
significance was set at P<0.05.
Results
LBH589 effect on ERα, PR and FoxA1. First of all, the effect 
of LBH589 on the expression of ERα and cognate PR (proges-
terone receptor) and FoxA1 (forkhead box A1) was studied. In 
estrogen-sensitive MCF-7 cells, LBH589 reduced the level of 
expression of all the three genes (Fig. 1), while MDA-MB-231 
cells did not express any of the genes under study, neither in 
basal condition nor after LBH589 treatment.
LBH589 effect on E-cadherin expression. E-cadherin was 
not expressed in untreated MDA-MB-231 cells; LBH589 
treatment increased E-cadherin gene expression, its effect 
being evident at doses ≥25 nM; a slight reduction of gene 
expression in E-cadherin positive MCF-7 cells was also 
observed (Fig. 2A). Western blotting for E-cadherin, reported 
in Fig. 2B, confirmed that increased gene expression resulted 
in the appearance of the protein in MDA-MB-231 cells; on 
the other hand, the reduction of E-cadherin gene expression 
Figure 2. Effect of LBH589 on E-cadherin expression and localization. (A) E-cadherin mRNA was evaluated in MDA-MB-231 and MCF-7 cells with 
real-time PCR. Results were normalized for three different housekeeping genes (β-actin, β2-microglobulin and L13A) and expressed as relative expression 
fold vs untreated controls (0 nM LBH589). Results are expressed as the means ± SD; n=3; **P<0.01; ***P<0.001. (B) Western blotting for E-cadherin was 
performed on membranes obtained from MDA-MB-231 and MCF-7 cells before and after treatment with 25 nM LBH589. Equal loading and transfer were 
verified by re-probing the blot with anti-tubulin antibodies. The image shows a typical experiment. (C) E-cadherin protein localization in MDA-MB-231 
and MCF-7 cells. Immunofluorescence for E-cadherin was performed on cells before and after 25 nM LBH589 treatment. Magnification, x400.
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observed in MCF-7 cells was not followed by a significant 
reduction of the protein level. LBH589 treatment determined 
also a correct expression of E-cadherin on the MDA-MB-231 
surface (Fig. 2C).
LBH589 effect on Slug, Snail and MTA3. Both E-cadherin 
repressors, Slug and Snail, were evaluated. As reported in 
Fig. 3, the expression of Slug and Snail was significantly 
enhanced by LBH589 treatment in both cell lines. Lastly, the 
Mi-2/NuRD macro-complex member MTA3 was studied. 
We observed that LBH589 significantly reduced the level of 
expression of MTA3 in both cell lines (Fig. 3, last row).
LBH589 effect on cell migration and invasion. To determine 
whether LBH589 had a role in MDA-MB-231 cell migration, 
a scratch wound assay was carried out. As shown in Fig. 4, 
the migration of treated cells was significantly reduced with 
respect to untreated controls. After 24 h, cells treated with 
25 nM LBH589 occupied only 15% of the wound compared 
to 33% occupation of untreated cells (P<0.001). Moreover, 
the role of LBH589 on the invasive potential of MDA-MB-
231 cells was assayed through the use of a transwell invasion 
chamber (Fig. 5). We observed that invasion of treated cells 
was markedly reduced compared with untreated cells after 
24 h (P<0.001). As reported also in Figs. 4 and 5, migration 
and invasion of MCF-7 cells were not affected by LBH589 
treatment.
LBH589 effect on CDH1 promoter. To evaluate whether 
LBH589 directly acts on CDH1 promoter inducing transcrip-
tion, a luciferase assay using a construct containing CDH1 
promoter was performed. We observed a significant increase 
in CDH1 promoter transcription level homogeneous with the 
increase of E-cadherin we reported above in MDA-MB-231 
Figure 3. Effect of LBH589 on Snail, Slug and MTA3 gene expression. Snail, Slug and MTA3 mRNA was evaluated in MDA-MB-231 and MCF-7 
cells treated with increasing doses of LBH589 (5-50 nM) with real-time PCR. Results were normalized for three different housekeeping genes (β-actin, 
β2-microglobulin and L13A) and expressed as relative expression fold vs untreated controls (0 nM LBH589). Results are expressed as the means ± SD; 
n=3; **P<0.01; ***P<0.001.
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cells; the direct effect of LBH589 on CDH1 promoter was 
observed even in MCF-7 cells (Fig. 6).
Discussion
The pan-deacetylase inhibitor LBH589 is a powerful anti-
tumour agent even at low nanomolar concentrations in a 
number of hematologic and solid tumours. It was, in addition, 
reported to induce re-expression of previously silenced genes 
modulating thus the behaviour of cancer cells (35-37).
The present report follows our previous observation in 
breast cancer cells where we observed a potent cytotoxic 
activity of LBH589 in both estrogen-sensitive and -insensi-
tive cells (16). Our present data demonstrate that LBH589 
induces E-cadherin gene expression in aggressive TNBC 
cells. E-cadherin gene expression resulted, furthermore, in the 
correct appearance of the cognate protein on MDA-MB-231 
surface and, the re-expression of E-cadherin caused a clear 
modification of MDA-MB-231 cell behaviour. In fact, after 
LBH589 treatment, cell migration and invasive potential were 
greatly reduced.
Our previous observation on the anti-proliferative and 
pro-apoptotic effects of LBH589 in ER-negative breast 
cancer cells has been recently confirmed by other authors 
(38). The same authors reported that the most induced gene by 
LBH589 treatment in MDA-MB-231 cells is the CDH1 gene 
that codes for E-cadherin, in total agreement with our obser-
vation on the increase of the CDH1 gene promoter activity 
Figure 4. Effect of LBH589 on MDA-MB231 and MCF-7 cell invasion. Scratch wound assay was performed on cells before and after treatment with 25 nM 
LBH589. A typical experiment is reported in the upper panels. Results, expressed as percent of occupied wound after 24 h with respect to T0, are reported in 
the lower panels; data are expressed as the mean ± SD; n=3; ***P<0.001.
Figure 5. Effect of LBH589 on MDA-MB231 and MCF-7 cell migration. 
Matrigel invasion assay was performed on cells before and after treatment 
with 25 nM LBH589. A typical experiment is reported in the upper panels. 
Results, expressed as number of invading cells/field, are reported in the lower 
panels; data are expressed as the mean ± SD; n=3; ***P<0.001. No significant 
migration of MCF-7 cells was observed in either condition.
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we report in the present study and consequent E-cadherin 
induction. Tate et al also noted an increase in the CDH1 
gene expression on the periphery of the primary tumour from 
MDA-MB-231 xenografts, and hypothesized that the induc-
tion of CDH1 expression by LHB589 at the invasive edge 
may be indicative of decreased metastatic potential. Actually, 
our observation in vitro of reduced migration and invasion of 
MDA-MB-231 cells treated with LBH589 substantiates their 
hypothesis, confirming that E-cadherin induction by LBH589 
has a functional meaning and could be exploited for thera-
peutic application.
It is also interesting to note that in ER-positive MCF-7 cells 
that express high level of E-cadherin, LBH589 is a clear anti-
proliferative and proapoptotic agent even at low nanomolar 
doses (16), but does not modify the E-cadherin expression and 
cell migration/invasion leaving unaffected the low metastatic 
potential of these cells.
As reported, in breast cancer MTA3/Snail/E-cadherin 
and estradiol (E2)/ERα signalling are closely linked (34). 
The appearance of E-cadherin in MDA-MB-231 cells 
treated with LBH589 could be due to the reactivation of ERα 
pathway in TNBC cells since other DCI were reported to act 
similarly  in several studies. For example, DCI in association 
with demethylating agents like 5-aza-2'-deoxycytidine were 
shown to reactivate ERα expression in ER-negative breast 
cancer cells (22,39,40); the DCI valproic acid was demon-
strated to enhance the efficacy of the anti-estrogen tamoxifen 
through increasing ER-mediated transcription (16) and also 
to induce ERα, PR, pS2 and FoxA1, giving to MDA-MB-231 
cells an estrogen-sensitive ‘phenotype’ and restoring their 
sensitivity to anti-estrogen therapy (18).
Controversial results on LBH589 effect on ERα expres-
sion in MDA-MB-231 cells, either receptor induction (23) or 
no effect at all (24), have been reported.
The present data confirm that LBH589 does not induce 
ERα expression and ER-pathway restoration in MDA-MB-
231 cells. Moreover, LBH589 reduced MTA3 levels, and 
significantly increased both Snail and Slug, whose levels 
are inversely related to E-cadherin expression, either in 
ER-negative MDA-MB-231 or in ER-positive MCF-7 cells. 
Furthermore, in MCF-7 cells LBH589 significantly decreased 
the expression level of ERα, PR and FoxA1, as previously 
reported (24). The effects of LBH589 on ER pathway are 
not consistent with those observed on E-cadherin gene and 
protein expression in both cell lines. It is thus conceivable 
that LBH589 can control E-cadherin independently of estra-
diol and this is not affected by the level of expression of Snail, 
in agreement with recent observations in ovarian carcinoma 
(41). Snail requires histone deacetylase activity to repress 
E-cadherin promoter and it has already been demonstrated 
that treatment with trichostatin A is sufficient to block this 
effect (42). Our data suggest that LBH589 in MDA-MB-231 
breast cancer acts directly on the CDH1 promoter and does 
not need to modify E-cadherin transcriptional repressors to 
induce E-cadherin expression and to modify the cell aggres-
sive attitude. In MCF-7 cells, even though LBH589 smoothens 
down the ER pathway, reducing MTA3 and increasing Snail 
and Slug, its direct action on CDH1 promoter is also present, 
the final effect on E-cadherin protein expression is irrel-
evant, so that migration and invasion of MCF-7 cells are not 
affected.
In conclusion, LBH589 is able to induce E-cadherin in 
highly aggressive TNBC cells reducing their migration and 
invasion, by-passing E-cadherin transcriptional repressors 
such as Snail and Slug and without any detectable effect on 
ERα expression and pathway. This compound can, there-
fore, be proposed for treatment of aggressive breast cancer, 
refractory to hormonal therapy exploiting its antiprolif-
erative and anti-invasive properties. At least eight different 
trials on advanced breast cancer treatment with LBH589 
both in monotherapy and in association with trastuzumab, 
capecitabine, lapatinib, or paclitaxel, respectively, are now 
listed on the site www.clinicaltrials.gov. We are looking 
forward to their conclusions and strongly hope LBH589 will 
be available soon for advanced breast cancer treatment.
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